

NOVO NORDISK A S  
Form 6-K  
November 08, 2010

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**November 8, 2010**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

---

Company Announcement

8 November 2010

Novo Nordisk A/S – Share repurchase programme

On 27 October 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.4 billion in the period from 27 October 2010 to 23 December 2010.

Since the announcement as of 1 November 2010, the following transactions have been made under the programme:

|                                        | <b>Number of</b>             | <b>Average Transaction value,</b> |            |
|----------------------------------------|------------------------------|-----------------------------------|------------|
|                                        | <b>shares purchase price</b> | <b>DKK</b>                        |            |
| <b>Accumulated, last announcement</b>  | 175,000                      | 96,793,388                        |            |
| 1 November 2010                        | 55,000                       | 557.9500                          | 30,687,250 |
| 2 November 2010                        | 67,500                       | 558.7176                          | 37,713,438 |
| 3 November 2010                        | 67,500                       | 551.7895                          | 37,245,791 |
| 4 November 2010                        | 70,000                       | 551.9342                          | 38,635,394 |
| 5 November 2010                        | 50,000                       | 548.9250                          | 27,446,250 |
| <b>Accumulated under the programme</b> | <b>485,000</b>               | <b>268,521,512</b>                |            |

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 82,550 B shares in the period from 1 November 2010 to 5 November 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

Company Announcement no 62 / 2010

Page 1 of 2

|                         |               |               |                 |          |
|-------------------------|---------------|---------------|-----------------|----------|
| <b>Novo Nordisk A/S</b> | Novo Allé     | Telephone:    | Internet:       | CVR no:  |
| Investor Relations      | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
|                         | Denmark       | Telefax:      |                 |          |

Edgar Filing: NOVO NORDISK A S - Form 6-K

+45 4444 6626

---

With the transactions stated above, Novo Nordisk owns a total of 27,102,205 treasury shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

*Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

Further information:

Media:

Investors:

Anne Margrethe Hauge Klaus Bülow Davidsen

Tel: (+45) 4442 3450 Tel: (+45) 4442 3176

[amhg@novonordisk.com](mailto:amhg@novonordisk.com) [klda@novonordisk.com](mailto:klda@novonordisk.com)

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

[krop@novonordisk.com](mailto:krop@novonordisk.com)

Jannick Lindegaard

Tel: (+45) 4442 4765

[jlis@novonordisk.com](mailto:jlis@novonordisk.com)

*In North America:*

*In North America:*

Lori Moore

Hans Rommer

Tel: (+1) 609 919 7991 Tel: (+1) 609 919 7937

[lrm@novonordisk.com](mailto:lrm@novonordisk.com) [hrrmm@novonordisk.com](mailto:hrrmm@novonordisk.com)

Company Announcement no 62 / 2010

Page 2 of 2

**Novo Nordisk A/S**

Novo Allé

Telephone:

Internet:

CVR no:

Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790

Denmark

Telefax:

+45 4444 6626

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 8, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer

---

